Disulfidptosis is a programmed cell death pathway in prostate cancer. A study in Scientific Reports has investigated the roles of genes related to disulfidptosis in disease pathogenesis and progression. The team developed a risk scoring model and then examined the relationship between this score and immune characteristics, somatic mutations and responses to therapy. Two disulfidptosis subtypes were identified: according to the risk score, the high-risk group demonstrated poorer progression-free survival and higher tumour mutational burden, associated with increased immune suppression; these high-risk features were linked to cancer pathways including IL-17 signalling. Drug sensitivity analysis suggested the potential for disulfidptosis-based personalized treatment strategies, as chemotherapy responses varied. PROK1 was identified as a prognostic marker, with reduced expression correlating with disease progression.

二硫线垂是前列腺癌中的一种程序性细胞死亡途径。Scientific Reports 上的一项研究调查了与双硫线垂相关的基因在疾病发病机制和进展中的作用。该团队开发了一个风险评分模型，然后检查了该评分与免疫特征、体细胞突变和对治疗的反应之间的关系。确定了两种双硫线细胞凋亡亚型： 根据风险评分，高危组表现出较差的无进展生存期和较高的肿瘤突变负荷，与免疫抑制增加有关;这些高危特征与癌症通路有关，包括 IL-17 信号传导。药物敏感性分析表明，由于化疗反应不同，基于二硫线下垂的个性化治疗策略具有潜力。PROK1 被确定为预后标志物，表达降低与疾病进展相关。